Moxifloxacina Mylan

Moxifloxacin, the active ingredient in Moxifloxacina Mylan, is a fluoroquinolone antibiotic presented as an oral formulation for systemic use. It treats a range of bacterial infections, including community‑acquired pneumonia, acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, skin and skin structure infections, and intra‑abdominal infections in adult patients.

GNH USA supplies Moxifloxacina Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and other healthcare providers worldwide.

Moxifloxacin is a fluoroquinolone antibiotic used to treat bacterial infections of the respiratory and other systems. - Community‑acquired bacterial pneumonia: eradicates causative pathogens and improves clinical outcomes. - Acute bacterial sinusitis: reduces sinus inflammation and bacterial load, leading to symptom relief. - Acute bacterial exacerbations of chronic bronchitis: resolves infection and helps prevent further deterioration. - Skin and skin structure infections: provides bacterial clearance in soft‑tissue infections. - Intra‑abdominal infections: contributes to eradication of mixed aerobic and anaerobic organisms.

Moxifloxacin may cause adverse reactions ranging from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools, usually self‑limiting. - Headache: transient cranial discomfort. - Rash: mild skin erythema or pruritus.

Serious or Rare Side Effects: - Tendon rupture: especially in the Achilles tendon. - QT interval prolongation: risk of cardiac arrhythmias. - Severe allergic reactions: anaphylaxis or angioedema. - Clostridioides difficile‑associated diarrhea: potentially life‑threatening colitis.

Before prescribing moxifloxacin, clinicians should consider several safety factors. - Renal or hepatic impairment: adjust therapy based on clinical judgment. - History of tendon disorders: avoid use due to risk of tendon rupture. - Cardiac arrhythmias: monitor QT interval, especially with other QT‑prolonging agents. - Pregnancy and lactation: use only if benefits outweigh risks, as safety data are limited. - Drug interactions: review concomitant medications for potential QT prolongation or CYP interactions. - Store at ambient temperature: keep below 25 °C, protect from moisture and direct sunlight.

Moxifloxacin can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concomitant use with other fluoroquinolones: increased risk of tendon toxicity. - Co‑administration with systemic corticosteroids: heightened tendon rupture risk. - Drugs that prolong QT interval (e.g., quinidine, macrolides): may cause serious cardiac arrhythmias. - Antacids containing aluminum or magnesium: significantly reduce absorption of moxifloxacin.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect; monitor INR. - Theophylline: possible increase in plasma concentrations; monitor for toxicity.